Huw Roddie

2.0k total citations
29 papers, 1.4k citations indexed

About

Huw Roddie is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Huw Roddie has authored 29 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 17 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Huw Roddie's work include Multiple Myeloma Research and Treatments (14 papers), Bone health and treatments (7 papers) and Cancer Treatment and Pharmacology (5 papers). Huw Roddie is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), Bone health and treatments (7 papers) and Cancer Treatment and Pharmacology (5 papers). Huw Roddie collaborates with scholars based in United Kingdom, France and Greece. Huw Roddie's co-authors include Gareth J. Morgan, Mark T. Drayson, Faith E. Davies, Roger G. Owen, Graham Jackson, J. Anthony Child, Sue Bell, Walter M. Gregory, Gordon Cook and Jenny Byrne and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Huw Roddie

27 papers receiving 1.4k citations

Peers

Countries citing papers authored by Huw Roddie

Since Specialization

Citations

This map shows the geographic impact of Huw Roddie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huw Roddie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huw Roddie more than expected).

Fields of papers citing papers by Huw Roddie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huw Roddie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huw Roddie. The network helps show where Huw Roddie may publish in the future.

Co-authorship network of co-authors of Huw Roddie

This figure shows the co-authorship network connecting the top 25 collaborators of Huw Roddie. A scholar is included among the top collaborators of Huw Roddie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huw Roddie. Huw Roddie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Myeloid sarcoma of uterine cervix: A case report with review of the literature 2022 ·Gynecologic Oncology Reports ·(unknown), (unknown), Huw Roddie, (unknown), (unknown)	3
2	Epilepsia partialis continua complicated by disseminated tuberculosis and hemophagocytic lymphohistiocytosis: a case report 2019 ·Journal of Medical Case Reports ·Gashirai K. Mbizvo, Isabel Lentell, Clifford Leen, Huw Roddie, Christopher P. Derry, Susan Duncan, (unknown)	8
3	Apixaban Is Safe and Effective Thromboprophylaxis in Myeloma Patients Treated with Immunomodulatory Therapy 2017 ·Blood ·(unknown), (unknown), Peter Johnson, Huw Roddie	0
4	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma 2014 ·Haematologica ·Meletios Α. Dimopoulos, Robert Z. Orlowski, (unknown), Pieter Sonneveld, KC Anderson, Meral Beksaç, Lotfi Benboubker, Huw Roddie, Anna Potamianou, (unknown), (unknown), Ö. Ataman, Helgi van de Velde, Paul G. Richardson	23
5	Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma 2013 ·Haematologica ·Meletios Α. Dimopoulos, Meral Beksaç, Lotfi Benboubker, Huw Roddie, (unknown), (unknown), (unknown), M. Mazier, (unknown), (unknown)	27
6	Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM) 2013 ·Blood ·Meletios Α. Dimopoulos, Robert Z. Orlowski, Thierry Façon, Pieter Sonneveld, Kenneth C. Anderson, Meral Beksaç, Lotfi Benboubker, Huw Roddie, Anna Potamianou, (unknown), Huaibao Feng, Ö. Ataman, Helgi van de Velde, Paul G. Richardson	2
7	Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results. 2012 ·Journal of Clinical Oncology ·Gareth J. Morgan, Graham Jackson, Faith E. Davies, Ping Wu, Walter M. Gregory, Sue Bell, Alexander J. Szubert, Nuria Navarro Coy, Mark T. Drayson, Roger G. Owen, Sylvia Feyler, John Ashcroft, Fiona Ross, Jennifer A. Byrne, Huw Roddie, Claudius Rudin, Kevin Boyd, Gordon Cook, J. Anthony Child	1
8	Epidemiology and clinical characteristics of parainfluenza virus 3 outbreak in a Haemato-oncology unit 2012 ·Journal of Infection ·Heli Harvala, Eleanor Gaunt, Chloe McIntyre, Huw Roddie, (unknown), Evonne T Curran, Richard Othieno, Peter Simmonds, J Bremner	27
9	Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial 2011 ·The Lancet Oncology ·Gareth J. Morgan, J. Anthony Child, Walter M. Gregory, Alex J. Szubert, Kim Cocks, Sue Bell, Nuria Navarro-Coy, Mark T. Drayson, Roger G. Owen, Sylvia Feyler, A. John Ashcroft, Fiona M. Ross, Jenny Byrne, Huw Roddie, Claudius Rudin, Gordon Cook, Graham Jackson, Ping Wu, Faith E. Davies	117
10	Cluster of non-tuberculous mycobacteraemia associated with water supply in a haemato-oncology unit 2011 ·Journal of Hospital Infection ·(unknown), Surabhi Taori, J. Dave, Lorna Willocks, Huw Roddie, Mary Hanson	24
11	A multi‐centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion 2011 ·British Journal of Haematology ·Miquel Lozano, Folke Knutson, R. Tardivel, Joan Cid, (unknown), (unknown), Huw Roddie, (unknown), (unknown), Claire D. Sherman, Lily Lin, (unknown), (unknown), C. V. Prowse	94
12	Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial. 2011 ·Journal of Clinical Oncology ·Faith E. Davies, Gareth J. Morgan, (unknown), Walter A. Gregory, (unknown), (unknown), Nuria Navarro Coy, Mark T. Drayson, (unknown), Sylvia Feyler, John Ashcroft, F. M. Ross, Jenny Byrne, Huw Roddie, Charles M. Rudin, Gary Cook, G Jackson, Kevin Boyd, J. Anthony Child	2
13	Granulocyte colony‐stimulating factor (G‐CSF) depresses angiogenesis in vivo and in vitro: implications for sourcing cells for vascular regeneration therapy 2010 ·Journal of Thrombosis and Haemostasis ·Olga Tura-Ceide, Jeffrey D. Crawford, G R Barclay, Kay Samuel, Patrick W. F. Hadoke, Huw Roddie, J. M. Davies, Marc L. Turner	23
14	A multi-center study of therapeutic efficacy and safety of platelet components prepared with pathogen inactivation (intercept (tm)) stored for 6 OR 7 days prior to transfusion 2010 ·Vox Sanguinis ·Miquel Lozano, (unknown), R. Tardivel, Joan Cid, (unknown), (unknown), Huw Roddie, (unknown), (unknown), Claire D. Sherman, L. Lin, (unknown), (unknown), (unknown)	7
15	A pilot study of the possibility and the feasibility of haemoglobin dosing with red blood cells transfusion 2010 ·Vox Sanguinis ·Håkon Reikvam, C. V. Prowse, Huw Roddie, Nancy M. Heddle, Tor Hervig, (unknown)	11
16	First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial 2010 ·The Lancet ·Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Kim Cocks, Sue Bell, Alex J. Szubert, Nuria Navarro-Coy, Mark T. Drayson, Roger G. Owen, Sylvia Feyler, A. John Ashcroft, Fiona Ross, Jenny Byrne, Huw Roddie, Claudius Rudin, Gordon Cook, Graham Jackson, J. Anthony Child	407
17	Dendritic cell vaccines in acute leukaemia 2008 ·Best Practice & Research Clinical Haematology ·(unknown), Huw Roddie	12
18	Optimal ex vivo expansion of neutrophils from PBSC CD34+ cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPO 2007 ·Journal of Translational Medicine ·Olga Tura-Ceide, G R Barclay, Huw Roddie, John Davies, Marc L. Turner	21
19	Absence of a relationship between immunophenotypic and colony enumeration analysis of endothelial progenitor cells in clinical haematopoietic cell sources 2007 ·Journal of Translational Medicine ·Olga Tura-Ceide, G R Barclay, Huw Roddie, John Davies, Marc L. Turner	22
20	Primary Non-Hodgkins Lymphoma of Muscle 1999 ·Clinical Oncology ·Leslie Samuel, (unknown), A M Lessells, Huw Roddie, (unknown)	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact